Tutti gli studi
AutorizzatoFase I e Fase II (Integrata) - AltroInterventistico

A Phase Ia/II Randomized Controlled Trial of Daratumumab Alone Versus Daratumumab Plus Abatacept for resistant active Antibody-Mediated Rejection in Kidney Transplant Recipients

When someone has a kidney transplant, their immune system can sometimes attack the donor organ. When this attack is driven by immune proteins called antibodies and does not improve with standard medicines, it is called resistant active antibody-mediated rejection. Without effective treatment, the transplanted kidney can be damaged and stop working. In this clinical trial, researchers are testing two targeted medicines: daratumumab and abatacept. Daratumumab works by reducing the immune cells that make harmful antibodies. Abatacept works by calming other immune cells that cause inflammation. Participants will receive either daratumumab alone or daratumumab combined with abatacept. The main aim of the trial is to see if these treatments are safe, how well they work to stop rejection, and whether combining the two medicines provides better protection for the kidney than using daratumumab by itself.

A colpo d'occhio

Stato
Autorizzato
Fase
Fase I e Fase II (Integrata) - Altro
Sponsor
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Obiettivo di iscrizione
20
Inizio
08 Sep 2026

Di cosa tratta questo studio?

A kidney transplant gives people with kidney failure a second chance at health. However, the body's immune system naturally sees the new kidney as foreign and may try to reject it. Doctors use anti-rejection medicines to prevent this, but sometimes an attack still happens. When immune proteins called antibodies attack the kidney, and standard treatments fail to stop it, doctors need new and more effective options.

This trial is looking at whether targeted immune therapies can stop this difficult-to-treat rejection. The main drug being tested is daratumumab. It targets specific cells in the immune system, known as plasma cells, which produce the damaging antibodies. By clearing these cells, doctors hope to halt the attack on the kidney.

Researchers also want to find out if adding a second drug, called abatacept, makes the treatment work even better. Abatacept works in a different way by blocking the signals that activate immune cells. By comparing daratumumab alone against daratumumab plus abatacept, the study aims to discover the safest and most effective way to help patients keep their donor kidneys working well for longer.

Punti chiave

  • Tests new treatments for kidney transplant rejection that has not improved with standard care.
  • Compares daratumumab on its own against daratumumab combined with abatacept.
  • Open to adults aged 18 and older with a transplanted kidney.
  • Study medicines are given as regular drips into a vein at the hospital.
  • Aims to stop the immune attack and keep the donor kidney working.

Chi può essere idoneo?

This trial is designed for adults aged 18 and older who have had a kidney transplant and are now experiencing active antibody-mediated rejection. To be considered, standard treatments for rejection must have been tried without success, meaning the rejection is considered 'resistant'.

Participants must have kidney function that is stable enough to take part safely, and they must be able to attend regular hospital appointments for infusions and monitoring. Both men and women are welcome to join.

You may not be able to take part if you have a serious active infection, other severe untreated health conditions, or known allergies to the study medications. The study team will carefully review your medical records, test results, and current medicines to confirm whether the trial is a safe choice for you.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. You are aged 18 or older.
  2. You have had a kidney transplant.
  3. You have active antibody-mediated rejection that standard care hasn't cured.
  4. You are well enough to attend regular hospital appointments.
  5. You do not have a severe, active infection.
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

Taking part involves receiving the study medications through an intravenous drip (an infusion into a vein) at a hospital clinic. Participants will be placed into one of two groups by chance: one group receives daratumumab alone, while the other receives both daratumumab and abatacept.

You will need to visit the hospital regularly for your infusions and health checks. During these visits, doctors will check your blood pressure, test your blood and urine, and see how well your kidney is coping. You may also need a kidney biopsy (where a tiny sample of tissue is taken) to check whether the rejection is improving.

The overall study typically lasts several months to a year, including the treatment period and follow-up visits. Your care team will give you a clear schedule so you know exactly when each appointment and test will take place.

Rischi e benefici potenziali

The main hope of taking part is that the treatment will calm your immune system and protect your transplanted kidney from failing. However, there is no guarantee of direct benefit. Because these medicines reduce immune system activity, the main risk is a higher chance of developing infections. You could also experience temporary reactions during the drip, such as fever, rash, or chills. Taking part is completely your choice, and you are free to leave the trial at any point without it affecting your normal medical care.

Luoghi (1)

Alcune posizioni dei siti sono approssimative. Stiamo migliorando questo — si prega di verificare con il team di prova prima di viaggiare.
  • —
    Non verificato
    Spagna

Domande comuni

What is antibody-mediated rejection?

It is a type of kidney rejection where your immune system produces harmful proteins called antibodies that attack and damage the donor kidney.

Will anyone in this study receive a dummy drug (placebo)?

No. All participants will receive active treatment with daratumumab, either on its own or alongside abatacept.

How are the study medicines given?

Both medications are given as an infusion through a small tube into a vein (an intravenous drip) at the hospital.

Do I have to stop my usual kidney transplant medicines?

Usually no. You will generally keep taking your regular anti-rejection medicines, but your doctors may adjust your doses during the study.

Posso abbandonare lo studio se cambio idea?

Yes. Taking part is voluntary. You can withdraw at any time, and your medical team will continue to provide standard care.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.